|
| 抗CD20单克隆抗体治疗B细胞淋巴瘤的效应机制 |
| Effector mechanisms of anti-CD20 monoclonal antibodies in killing B-cell lymphoma |
| 投稿时间：2014-06-04 修订日期：2014-06-04 |
| DOI： |
| 中文关键词: B细胞淋巴瘤 CD20 抗CD20单克隆抗体 |
| 英文关键词: B-cell lymphoma CD20 anti-CD20 monoclonal antibodies |
| 基金项目: |
|
| 摘要点击次数: 625 |
| 全文下载次数: 0 |
| 中文摘要: |
| B细胞淋巴瘤是一种主要的非霍奇金淋巴瘤(non-Hodgkin’s lymphoma,NHL), 95%以上的B细胞淋巴瘤均表达B细胞分化抗原CD20。尽管目前CD20在B细胞分化发育过程中的具体功能尚未阐明,但其特有的表达方式和在细胞膜上的分布特点决定了其成为B细胞淋巴瘤靶向治疗的主要靶点。近十年来,随着抗CD20单克隆抗体的不断发展和进步,联合传统的CHOP化疗方案,在NHL的治疗中显示出良好的效果。本文就抗CD20单克隆抗体在治疗淋巴瘤中的作用机制及潜在的弊端做一简要的概述。 |
| 英文摘要: |
| B-cell lymphoma is one major kind of non-Hodgkin’s lymphoma(NHL), and more than 95 percents of B-cell lymphomas have B-cell differentiation antigen—CD20 expressed on cellular surface. Although the function of CD20 in B-cell development is not clear, of which the expression pattern and distribution feature in cytoplasmic membrane have made CD20 the primary therapeutic target in B-cell lymphoma. During recent years, combined with CHOP chemotherapy, some of new-type anti-CD20 monoclonal antibodies have emerged and showed great therapeutic effects in NHLs. This review illustrated the effector mechanisms and some disadvantages of anti-CD20 monoclonal antibodies in treating B-cell lymphomas. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |
